Download the report now
Drug claims and
utilization data for:
Partner insurers
Third-party payors
Download the report now
Read the full report
Read the full report
Claimants
Specialty Drugs
Trend insights
Hover over each icon
Biologics and biosimilars
Non-specialty drugs
Cost concentration
A focus on tangible solutions
Hover over each box
Cost
management
Cost
management
+ Biosimilar strategies
+ PPNs
+ PLAs
Contact us to learn more
Contact us to learn more
Our offices
Hover for contact information
Windsor
1.844.422.4260
Québec City
1.844.201.1012
Toronto
1.844.201.1012
Contact us to learn more
email: information@hbmplus.ca
email: information@hbmplus.ca
2021
Representing
Trend insights
Hover over each icon
A focus on tangible solutions
Hover over each box
2M+
Annual drug spend
$1.9B
+
Drug Trends & strategic insights
+
In 2020 over 23,000 claimants utilized a specialty drug product
for the treatment of their condition.
Specialty drugs
Total drug cost for biosimilars reached $20.7 million, which represents an increase of 54.8% from the previous year.
HBM+ is seeing a growing utilization of biologic drugs to treat relatively common conditions.
Top 5% of claimants are responsible
for 53.8% of overall drug costs.
+
Partner insurers
+
In 2020 over 23,000 claimants utilized a specialty drug product for the treatment of their condition.
Specialty drugs
In 2020 over 23,000 claimants utilized a specialty drug product for the treatment of their condition.
Biologics and biosimilars
Total drug cost for biosimilars reached $20.7 million, which represents an increase of 54.8% from the previous year.
+ Biosimilar strategies
+ PPNs
+ PLAs
Cost
management
+ Digital pharmacy
+ Mental health
+ Drug pipeline
Emerging &
future trends
Emerging & future trends
Emerging & Future Trends
+ Digital pharmacy
+ Mental health
+ Drug pipeline
Emerging & Future Trends